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Based on the epidemiologic findings of Covid-19 incidence; illness and mortality seem to be
associated with metabolic risk factors. This systematic review and meta-analysis aimed to
assess the association of metabolic risk factors and risk of Covid-19.
Methods
This study was designed according to PRISMA guidelines. Two independent researchers
searched for the relevant studies using PubMed, Web of Science, Cochrane Library, and
Scopus. The search terms developed focusing on two main roots of “Covid-19” and “meta-
bolic risk factors”. All relevant observational, analytical studies, review articles, and a
meta-analysis on the adult population were included in this meta-analysis. Meta-analysis
was performed using the random effect model for pooling proportions to address hetero-
geneity among studies. Data were analyzed using STATA package version 11.2, (Stata-
Corp, USA).
Results
Through a comprehensive systematic search in the targeted databases we found 1124
papers, after running the proses of refining, 13 studies were included in the present
meta-analysis. The pooled prevalence of obesity in Covid-19 patients was 29% (95%
CI: 14–47%). For Diabetes and Hypertension, these were 22% (95% CI: 12% 33%) and
32% (95% CI: 12% 56%), respectively. There was significant heterogeneity in the esti-
mates of the three pooled prevalence without any significant small-study effects. Such
warning points, to some extent, guide physicians and clinicians to better understand the
importance of controlling co-morbid risk factors in prioritizing resource allocation and
interventions.
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Conclusion
The meta-analysis showed that hypertension is more prevalent than obesity and diabetes in
patients with Covid-19 disease. The prevalence of co-morbid metabolic risk factors must be
adopted for better management and priority settings of public health vaccination and other
required interventions. The results may help to improve services delivery in COVID-19
patients, while helping to develop better policies for prevention and response to COVID-19
and its critical outcomes.
1. Introduction
From December 2019, coronavirus disease −2019 (COVID-19) that was reported from
Wuhan-China, quickly became a global pandemic. Due to the speed of the spread and the
severity of individual and social complications and consequences, pandemic unexpectedly has
resulted in a significant strain on healthcare systems [1, 2].
Because of the unknown complex nature of the disease, there are many doubts about the
related and predisposing factors. Initially, the disease with prominent symptoms of the pul-
monary respiratory system was thought to be more severe in the elderly [1, 3]. At the same
time, in a very short period of time, the virus surprised the health care workers with the
speed of changing the patterns of clinical symptoms and ddifferent impact in diverse target
groups [4, 5].
Based on the epidemiologic findings of COVID-19 incidence, the severity of illness, and
mortality seem to be associated with multiple comorbidities such as diabetes, hypertension,
and cardiovascular disease [1, 6]. Some studies revealed that severe COVID-19 patients have a
higher incidence of diabetes and hypertension than milder forms [7, 8]. There are scattered
researches on the association between obesity and overweight and the risk of disease [6]. There
is also different evidence from the results of treatment protocols and intensive care unit out-
comes that emphasizes the association between metabolic risk factors and the consequences of
different interventions [1, 8, 9].
Policymakers and health managers need reliable information to help them make accurate
decisions and take timely and effective actions [5]. Comprehensive analysis of applied research
can help policymakers to make decisions on screening plans for high-risk groups. High prior-
ity should be given to patients with COVID-19 infection who also simultaneously suffer from
metabolic risk factors. This approach may even influence clinical decisions such as tracking of
diabetics or hypertensive who are registered as COVID-19 patients or even how to distribute
and allocate inpatient, emergency facilities, and intensive care. Despite or the priority of the
problem, there is an evident gap in practical comprehensive documents on the association of
metabolic risk factors and Covid-19 [1, 10, 11]. Therefore, to get more convincing results, we
aimed to conduct a systematic review addressed the association between the presence of the
metabolic risk factors and the risk of Covid-19 incidence in the adult population.
2. Methods
Aimed to assess the association between metabolic risk factors and Metabolic syndrome
(MetS) and Covid-19 we followed the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [12].
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2.1. Data source and search strategy
Based on developed protocol, systematically, all available related papers searched from com-
prehensive international databases of PubMed and NLM Gateway (for MEDLINE), Institute
of Scientific Information (ISI), Cochrane library, and Scopus, from inspection of disease to 7
Jun 2020. Regardless of the time of the study or the date of publication of the results and the
language of the published articles, all relevant studies were included in the processes of
refinement.
The main roots for the development of search strategies formed on the basis of “Covid-19”
and components of “metabolic risk factors”. The components of metabolic risk factors were:
obesity/overweight; Diabetes (T2DM); hypertension and hypercholesterolemia. We also spe-
cifically searched for relevant studies on metabolic syndrome (MetS). In completing this syn-
tax; all related terms included according to this main strategy (Table 1). In addition, the
reference lists and cited articles of the included papers were searched manually to find any
additional papers.
2.2. Inclusion and exclusion criteria
This systematic review included all relevant observational, analytical studies, review articles,
and meta-analysis on the adult population. There was not any restriction in terms of countries,
ethnicity, and gender of the participants. There was no time limit for studying or publishing
articles or the language of publication of results.
We excluded non-human-based studies or those with duplicate citations. The studies that
focused on non-generalized specific sub-group populations were also excluded. Studies with
duplicate citations were excluded. In the situation of multiple publications on the same popu-
lation, only the largest study or the main source of data was included. Moreover, if there were
any low-quality papers that had no eligible data for collection it was deleted.
2.3. Study selection
After conducting the searches, all of the results saved into the Endnote software. All records
refined for three sequential steps of relevancy assessment, which was run according to the eval-
uation of titles, abstracts, and full texts, respectively. Remained papers evaluated for their qual-
ity (Fig 1).
The quality assessment of remained papers conducted, independently, by two research
experts. The quality of study design, sampling strategy, and measurement quality assessed
based on Consort 2010 check list and Jadad scoring for clinical trials and STROBE quality
assessment tools for observational studies (cohort, case-control, and cross-sectional studies).
2.4. Data extraction
For remained relevant papers, based on the PRISMA 2009 statement checklist, the quality
assessment of the studies evaluated, and using a customized form, relevant data were indepen-
dently extracted from eligible papers. The following data were extracted: first author, year of
publication, country, research design, sources of the patients, types of the study population,
sample size, the patient’s demographic data, the status of metabolic risk factors by types of
diagnostic indicators and specific units, Covid-19 and diagnostic criteria, recommendations,
and specific practical points.
All the sequential process of systematic search, refinement of papers, quality assessment
and data extraction were followed independently by two independent researchers (Kappa
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statistic for agreement for quality assessment; 0.92). Probable discrepancy resolved through
referencing the principal investigator’s opinions’.
2.5. Statistical analysis
Meta-analysis was performed by means of the STATA package version 11.2 (Stata Corpora-
tion, College Station, TX, USA) to combine the prevalence of all studies and conclude the
pooled prevalence and its 95% confidence interval (CI) using a random effect model for pool-
ing proportions [13]. Forest plots were drawn showing the variation of the prevalence among
all studies together with the pooled measure [14]. Between-study heterogeneity was evaluated
by the Cochran’s Q test and the I2 statistic [15]. A fixed-effects model was applied (P > 0.05 or
Table 1. Search strategy.
PubMed
((((covid[Title/Abstract]) OR "COVID-19"[Title/Abstract]) OR coronavirus[Title/Abstract])) AND
((((((("Metabolic Syndrome"[Mesh]) OR (((((((((((((((((((("X Syndrome"[Title/Abstract]) OR "Syndrome X"[Title/
Abstract]) OR "Insulin Resistance"[Title/Abstract]) OR Diabetes[Title/Abstract]) OR "HDL"[Title/Abstract]) OR
"LDL"[Title/Abstract]) OR "hyper lipid"[Title/Abstract]) OR "TG"[Title/Abstract]) OR "hyper cholesterol"[Title/
Abstract]) OR cardiometabolic[Title/Abstract]) OR cardio-metabolic[Title/Abstract]) OR "cardio metabolic"[Title/
Abstract]) OR "blood pressure"[Title/Abstract]) OR systolic[Title/Abstract]) OR diastolic[Title/Abstract]) OR
triglyceride[Title/Abstract]) OR cholesterol[Title/Abstract]) OR overweight[Title/Abstract]) OR waist to hip ratio
[Title/Abstract]) OR waist- hip ratio [Title/Abstract]) OR waist circumference [Title/Abstract]) OR obesity[Title/
Abstract]) OR "BMI"[Title/Abstract])) OR "Obesity, Abdominal"[Mesh]) OR (("Body Mass Index"[Mesh]) OR
"Overweight"[Mesh])) OR "Diabetes Mellitus"[Mesh]) OR "Cholesterol, LDL"[Mesh]) OR (((("Fasting plasma
glucose"[Title/Abstract]) OR "Fasting Blood glucose"[Title/Abstract]) OR "FPG"[Title/Abstract]) OR "FBS"[Title/
Abstract]))
Scopus
( (TITLE-ABS-KEY (covid) OR TITLE-ABS-KEY (coronavirus) ) ) AND ( ( ( (TITLE-ABS-KEY ("Metabolic
Syndrome") OR TITLE-ABS-KEY ("Syndrome X") OR TITLE-ABS-KEY ("X Syndrome") OR TITLE-ABS-KEY
("Insulin Resistance") OR TITLE-ABS-KEY ("Diabetes") OR TITLE-ABS-KEY ("HDL") OR TITLE-ABS-KEY
("LDL") OR TITLE-ABS-KEY ("hyper lipid") OR TITLE-ABS-KEY ("TG") ) ) OR ( (TITLE-ABS-KEY ("hyper
cholesterol") OR TITLE-ABS-KEY ("cardiometabolic") OR TITLE-ABS-KEY ("cardio metabolic") OR
TITLE-ABS-KEY ("cardio-metabolic") OR TITLE-ABS-KEY ("blood pressure") OR TITLE-ABS-KEY (systolic) OR
TITLE-ABS-KEY (diastolic) OR TITLE-ABS-KEY (triglyceride) OR TITLE-ABS-KEY (cholesterol) ) ) ) OR (
(TITLE-ABS-KEY ("overweight") OR TITLE-ABS-KEY (obesity) OR TITLE-ABS-KEY ("BMI") OR
TITLE-ABS-KEY ("Body mass index") OR TITLE-ABS-KEY (" waist to hip ratio ") OR TITLE-ABS-KEY (" waist-
hip ratio ") OR TITLE-ABS-KEY (" waist circumference ") OR TITLE-ABS-KEY ("Fasting plasma glucose") OR
TITLE-ABS-KEY ("Fasting blood glucose") OR TITLE-ABS-KEY ("FPG") OR TITLE-ABS-KEY ("FBS") ) ) ) AND
(EXCLUDE (DOCTYPE, "le") OR EXCLUDE (DOCTYPE, "ed") OR EXCLUDE (DOCTYPE, "sh") OR EXCLUDE
(DOCTYPE, "cp") OR EXCLUDE (DOCTYPE, "ch") OR EXCLUDE (DOCTYPE, "er") OR EXCLUDE (DOCTYPE,
"bk") ) AND (EXCLUDE (SUBJAREA, "ENVI") OR EXCLUDE (SUBJAREA, "COMP") OR EXCLUDE
(SUBJAREA, "SOCI") OR EXCLUDE (SUBJAREA, "ARTS") OR EXCLUDE (SUBJAREA, "ENGI") OR EXCLUDE
(SUBJAREA, "MATE") OR EXCLUDE (SUBJAREA, "MATH") OR EXCLUDE (SUBJAREA, "PHYS") ) AND
(EXCLUDE (DOCTYPE, "no") ) AND (EXCLUDE (SRCTYPE, "k") )
ISI/WOS
TOPIC: (covid) OR TOPIC: (coronavirus)
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC
Timespan = All years
TOPIC: ("Metabolic Syndrome") OR TOPIC: ("X Syndrome") OR TOPIC: ("Insulin Resistance") OR TOPIC:
(Diabetes) OR TOPIC: ("HDL") OR TOPIC: ("Blood Glucose") OR TOPIC: ("LDL") OR TOPIC: ("hyper lipid") OR
TOPIC: ("TG") OR TOPIC: (cholesterol) OR TOPIC: (cardiometabolic) OR TOPIC: ("cardio metabolic") OR
TOPIC: ("cardio-metabolic") OR TOPIC: ("blood pressure") OR TOPIC: (systolic) OR TOPIC: (diastolic) OR
TOPIC: (triglyceride) OR TOPIC: (overweight) OR TOPIC: (obesity) OR TOPIC: (waist to hip ratio) OR TOPIC:
(waist-hip ratio) OR TOPIC: (waist circumference)
OR TOPIC: ("LDL") OR TOPIC: ("BMI") OR TOPIC: ("Body mass index") OR TOPIC: ("Fasting plasma glucose")
OR TOPIC: ("blood glucose") OR TOPIC: ("FPG") OR TOPIC: ("FBS")
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC
Timespan = All years
https://doi.org/10.1371/journal.pone.0243600.t001
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I2< = 50%). Otherwise, a random-effect model was applied (P< 0.05 or I2 greater than 50%).
Presence of small-study effects (ie, whether smaller studies tend to give substantially larger esti-
mates of effect size compared with larger studies) was assessed using the Egger’s regression
asymmetry test [16, 17]. All p-values were two-tailed.
2.6. Ethical considerations
The present study has been approved by the ethical committee of non-governmental Pars
Advanced and Minimally Invasive Medical Manners Research Center of Pars Hospital, Teh-
ran, Iran. All of the included studies in our review would be cited in all reports and all
extracted publications of our study. For more required information we contacted the corre-
sponding author.
3. Results
Running the search strategy initially led to a total of 1124 articles. After removing duplicates,
checked the relevancy of titles and abstracts, and reviewing the full-texts, 47 studies remained
for analysis (Fig 1). Through rechecking the records, we found that thirty studies related to
Fig 1. Papers search and review flowchart for selection of primary study.
https://doi.org/10.1371/journal.pone.0243600.g001
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China and nine studies related to the USA. In China, there were one nation-wide and 29 local
studies in which we were to select that one national-wide study and 3 other local studies and
omitted the other 26 local studies due to time overlap with those four main selected ones.
In the USA, on the other hand there, there were nine studies that 3 of them were national-
wide and 6 of them were local. From those 3 national-wide ones we chose the largest study
that belongs to CDC and all the other studies were again omitted due to time overlap. Finally,
thirteen studies related to 10 countries remained in the final analysis. Besides, studies related
to Italy and Spain was nation-wide and the study related to the UK was a region-wide study.
Thus, we select the most comprehensive sources of data. The features of the 13 studies were
shown in Table 2.
All included studies were retrospective in design (Cohort or Cross-sectional). The diagnosis
of Covid-19 was based on World Health Organization’s interim guidance in all studies (by
RT-PCR). These studies were the ones reported on the prevalence of metabolic risk factors
(diabetes, obesity, and hypertension).
A total sample of 2,602, 7,632, and 15,268 patients with Covid-19 was included in our analysis
of obesity, diabetes, and hypertension, respectively. There was not any study that specifically
focused on MetS. The prevalence of hyperglycemia was reported only through one paper (28%).
The mean age for diabetes and hypertension analysis based on what reported (from only six
studies) was 55.25 years and about 61% of patients were males in all three analysis. The maxi-
mum number of cases was 7,162 and belongs to the USA, whereas the minimum was 91 and
belongs to Singapore.
The prevalence of diabetes was reported on all 13 studies while 10 of them reported the
patient’s hypertension prevalence and only 5 of them reported the patient’s obesity prevalence.
This prevalence was not reported in terms of sex or age groups so we were not able to perform
sub-group analysis.
3.1. Prevalence of obesity in Covid-19 patients
The pooled prevalence of Obesity was 29% (95% CI: 14–47%). There was obvious heterogene-
ity (I2: 97.94%, p< 0.001) in the prevalence of obesity in these studies (Fig 2). The Egger’s test
p-value was 0.19 which means there is no indication of small-study effects.
Several sensitivity analyses were done to test the robustness of the observed association.
Elimination of any single study at a time from the meta-analysis did range from 25% (95% CI:
8.4%-42%) to 35% (95% CI: 21%-49%) that indicate moderate robustness of the pooled esti-
mates of prevalence (Fig 3).
3.2. Prevalence of diabetes in Covid-19 patients
The pooled prevalence of Diabetes was 22% (95% CI: 12% 33%). There was obvious heteroge-
neity (I2: 99.47%, p< 0.001) in the prevalence of Diabetes in these studies (Fig 4). The Egger’s
test p-value was 0.27 which means there is no indication of small-study effects.
Several sensitivity analyses were conducted to test the robustness of the observed associa-
tion. The exclusion of any single study at a time from the meta-analysis did range from 22%
(% CI: 11%-33%) to 25% (95% CI: 13%-38%) that indicate very high robustness of the pooled
estimates of prevalence (Fig 5).
3.3. Prevalence of hypertension in Covid-19 patients
The pooled prevalence of hypertension was 32% (95% CI 12% 56%). There was obvious het-
erogeneity (I2 99.74%, p < 0.001) in the prevalence of obesity in these studies (Fig 6). The
Egger’s test p-value was 0.63 which means there is no indication of small-study effects.
PLOS ONE Metabolic risk factors and Covid-19
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Fig 2. Forest plots of pooled prevalence of obesity in Covid-19 patients.
https://doi.org/10.1371/journal.pone.0243600.g002
Fig 3. Forest plots of sensitivity analyses of each included study in meta-analysis of the prevalence of obesity in
Covid-19 patients.
https://doi.org/10.1371/journal.pone.0243600.g003
Fig 4. Forest plots of pooled prevalence of diabetes in Covid-19 patients.
https://doi.org/10.1371/journal.pone.0243600.g004
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Several sensitivity analyses were conducted to test the robustness of the observed associa-
tion. The exclusion of any single study at a time from the meta-analysis did range from 27%
(% CI 17%-38%) to 37% (95% CI 18%-56%) that indicate moderate robustness of the pooled
estimation of prevalence (Fig 7).
The results showed the estimated pooled prevalence of obesity, diabetes, and hypertension
was 29%, 22%, and 32% respectively. So, the pooled prevalence of hypertension is the highest
and the pooled prevalence of diabetes is the lowest ones. This means, in other words, that
hypertension is more prevalent than obesity and diabetes in patients with Covid-19 infection.
4. Discussion
To the best of our knowledge present investigation as one of the pioneers’ comprehensive ana-
lytical studies on the association of Metabolic risk factors and risk of Covid-19, summarized
practical findings of related evidence and provide a wide range of information to policymakers,
clinical specialists, researchers, and other stakeholders.
Fig 5. Forest plots of sensitivity analyses of each included study in meta-analysis of the prevalence of diabetes in
Covid-19 patients.
https://doi.org/10.1371/journal.pone.0243600.g005
Fig 6. Forest plots of pooled prevalence of hypertension in Covid-19 patients.
https://doi.org/10.1371/journal.pone.0243600.g006
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Present meta-analysis has collected data from all observational studies on Covid-19 patients
with obesity/overweight, diabetes mellitus, hypertension, and dyslipidemia in the world. The
diagnosis of SARS COV-2 was by RT-PCR (based on the World Health Organization interim
guidance).
Consistent with previous reports, we found a considerable prevalence of metabolic risk fac-
tors, which most likely act as a risk factor, in COVID-19 patients. The pooled prevalence of
obesity in Covid-19 patients was 29% (95% CI: 14–47%). For Diabetes and hypertension these
were 22% (95% CI: 12% 33%) and 32% (95% CI 12% 56%), respectively. This indicates that
hypertension (32%) is more prevalent than obesity (29%) than diabetes (22%) in patients with
Covid-19 infection.
There were significant and high levels of heterogeneity (more than 95%) for the pooled
prevalence of obesity, diabetes, and hypertension. The existing heterogeneity could be partly
due to sampling size, design, the study scope, screening methods, and diagnostic method,
which was not solved by our sensitivity analysis.
In the sensitivity analysis, the exclusion of any study did not have a significant impact on
the pooled estimates, which displayed a rather low sensitivity. Our guess is that a variety of
study scope (national, regional, and local) have led to heterogeneity. However, due to the
scarce number of studies, we could not check it through a meta-regression analysis.
Yet, we can rely on these estimates, as the small study effects that were checked by Egger’s
test showed no significant indication of any effects on the pooled prevalences.
Based on the raised probabilities, metabolic risk factors could be associated with the possi-
bility of infection and even the severity of symptoms and consequences of the Covid-19 disease
[9, 25, 27].
It is mentionable that; in early clinical reports, obesity/ overweight was rarely noticed
among the significant clinical risk factors for Covid-19. Complementary findings emphasized
on a high frequency of obesity among patients admitted to intensive care for Covid-19 disease
[26, 28–30].
In line with the findings of the present study, a previous study discussed that patients
with T2DM are susceptible to infections of the lower (but not upper) respiratory system
[31]. People with T2DM are more susceptible to Covid-19 infection, with twice as high
Fig 7. Forest plots of sensitivity analyses of each included study in meta-analysis of the prevalence of hypertension
in Covid-19 patients.
https://doi.org/10.1371/journal.pone.0243600.g007
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mortality risk as metabolically healthy people [5]. Another evidence revealed that compared
with non-diabetic patients, patients with diabetes are more likely to be admitted to hospital
[31, 32]. Some related studies have also emphasized the role of hypertension as a risk factor
of Covid-19 disease [33, 34].
Investigate the possible causes of these associations; exceed weight has been described as an
independent predisposition factor for severe pulmonary infections [35]. Besides, abdominal
obesity results in reduced blood oxygen saturation through impairing the processes of ventila-
tion, especially at the base of the lungs [6]. As another confirmed reason, the abnormal secre-
tion of adipokines and cytokines characterize a chronic low-grade inflammation situation of
abdominal obesity, that could impair immune responses [7].
It is still unknown whether obesity or diabetes acts as a risk factor for the prognosis of
COVID-19. As the most likely mechanism T2DM is widely proposed as a chronic, low-grade
inflammatory disease caused by an imbalance of long term immune system, metabolic syn-
drome, or nutrient excess associated with excess weight and obesity. Obesity-associated
inflammation, which characterized by increasing abundance and activation of innate and
adaptive immunity cells in adipose tissue along with an increased release of inflammatory fac-
tors and chemokines locally and systemically [22, 36].
Hypertension studied as a host risk factor for Covid-19 may underscore the involvement of
the renin-angiotensin system (RAS) in the pathogenesis of the disease [33, 34].
It has been accepted that through a complex setting, some comorbidities frequently coexist.
For instance, diabetes frequently coexists with hypertension, obesity, or even coronary heart
diseases [21, 23]. In these situations, patients with coexisting metabolic risk factors are more
likely to be at risk of debases and poorer outcomes [21].
Practically based on the recommendations of most studies considering the variations of pat-
terns and different trends in a different population [5], Patients with cardiometabolic risk fac-
tors and especially those with multiple risk factors should take extra measures to avoid Covid-
19 contamination by enforcing [26]. In this regard further studies, particularly those enrolling
different participants from various groups, are needed to validate the practical findings [25].
The present investigation has some strengths and limitations. This attempt was the first
comprehensive systematic review and meta-analysis on the association of metabolic risk fac-
tors and Covid-19 disease. Most of the included studies were benefitting from the retrospective
cohort design provide related data from interactive new databases. In all papers diagnosis of
Covid-19 was based on World Health Organization interim guidance in all studies (by
RT-PCR).
As one of the mentionable limitations, as like any other secondary study, the quality of our
data was dependent on the accuracy and quality of the data reported in the primary studies.
Due to the limited number of studies and heterogeneity of reported specification we were not
able to analyze the data in subgroups of sex, age, ethnicity, and other practical fields. As
another hint, many potential factors such as physical activity, smoking, alcohol consumption,
job description, and education, were not controlled.
As the most important implications; results of present meta-analysis reveal important infor-
mation for both; policymakers and the general population to protect them against the con-
firmed risk of disease. This report showing the prevalence of metabolic risk factors in patients
with Covid-19, which is beneficial to management and inhibit the spread of disease in the
future. As the main suggestions:
• Co-occurrence of metabolic risk factors in suspected individuals or definite cases of Covid-
19 require close cooperation between different specialists in order to carry out an appropri-
ate clinical evaluation process for each individual as soon as possible.
PLOS ONE Metabolic risk factors and Covid-19
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• Given the limitations of diagnostic capacities and medical services, as well as the possibility
of imminent production of vaccines or more approved therapies, it is necessary to plan for
prioritizing the availability of these groups and the allocation of future facilities.
• Special attention should be paid to this group of COVID-19 patients as they may suddenly
develop acute heart complications or problems that alter their recovery.
• Proper triage of these groups of patients based on a comprehensive evaluation of metabolic
risk factors provides appropriate supporting plan through which prompt protective proce-
dure follows by health providers and patients themselves.
• Another important point is to pay attention to the accurate collection and recording of data
that can help analyze the health status of these groups and allow them to be followed up after
diagnose/ discharge.
• Cardiometabolic prevention must be considered as the most important priority through the
post-pandemic recovery phase of COVID-19. These require significant investment in inter-
ventions addressed health-promoting and lifestyle promotion.
• In addition, more activities should be made to compensate for the above-mentioned limita-
tion in future studies.
5. Conclusion
In summary, by identifying host risk factors associated COVID-19 this study shed light on the
underlying mechanisms of disease progression. The results may help in the promotion of
patient management while helping to develop better policies for prevention and response to
COVID-19 and its critical outcomes. The prevalence of co-morbid metabolic risk factors must
be adopted for better management and priority settings of public health vaccination and other
required interventions. Considering the evident gap in related evidence, more adequately pow-
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